Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy

Accumulating preclinical evidence indicates that Toll-like receptor (TLR) agonists efficiently boost tumor-targeting immune responses (re)initiated by most, if not all, paradigms of anticancer immunotherapy. Moreover, TLR agonists have been successfully employed to ameliorate the efficacy of various...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncoimmunology
Autores principales: Iribarren, Kristina, Bloy, Norma, Buqué, Aitziber, Cremer, Isabelle, Eggermont, Alexander, Fridman, Wolf Hervé, Fucikova, Jitka, Galon, Jérôme, Špíšek, Radek, Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo
Formato: Artigo
Lenguaje:Inglês
Publicado: Taylor & Francis 2015
Materias:
Review
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4839356/
https://ncbi.nlm.nih.gov/pubmed/27141345
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1088631
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares